Stock YP1A IMMUTEP ADR
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Market Closed - Deutsche Boerse AG
Other stock markets
 03:50:54 2024-06-28 EDT 		5-day change 1st Jan Change
1.85 EUR +1.65% Intraday chart for Immutep ADR -20.26% -12.74%
06-27 ADRs End Flat; Alarum Technologies Climbs 26% DJ
06-27 Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ADRs End Flat; Alarum Technologies Climbs 26%
DJ
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data
MT
Immutep Reports Positive Results in Drug Combination Trial for Head, Neck Cancer
MT
Immutep Gets Exclusive Rights to Develop, Commercialize New Anti-LAG-3 Small Molecules
MT
Immutep Signs Agreement with Cardiff University for Development Cancer Treatment
MT
Immutep Completes Nearly AU$11 Million Retail Entitlement Offer
MT
Immutep Completes Stock Offering
MT
Rights Issue: 1 new share @ 0.38 AUD for 16 existing shares
FA
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy
MT
Immutep Raising AU$100 Million for Phase Three Trial
MT
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial
CI
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data
MT
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024
CI
Immutep Limited Announces Initial Clinical Data from EFTISARC-NEO
CI
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial
MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024
CI
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck
MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMM Stock
  4. YP1A Stock
  5. News Immutep ADR
  6. Highlights